Literature DB >> 10363140

Locally advanced breast cancer.

F J Esteva1, G N Hortobagyi.   

Abstract

The multidisciplinary management of patients with locally advanced breast cancer (LABC) has evolved over the last three decades. The introduction of chemotherapy (CT) and endocrine therapy in conjunction with surgery and radiation therapy (XRT) have changed the natural history of this disease. The authors discuss the role of the taxanes, novel endocrine therapy, and high-dose CT programs in the management of LABC. Indications for breast-conserving surgery are presented. The role of prognostic and predictive tumor markers in LABC is discussed.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10363140     DOI： 10.1016/s0889-8588(05)70065-4

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  11 in total

1.  Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.

Authors:  Francisco J Esteva; Stacy L Moulder; Ana M Gonzalez-Angulo; Joe Ensor; James L Murray; Marjorie C Green; Kimberly B Koenig; Mong-Hong Lee; Gabriel N Hortobagyi; Sai-Ching Yeung
Journal:  Cancer Chemother Pharmacol       Date:  2012-09-28       Impact factor: 3.333

2.  Evaluation of neoadjuvant chemotherapy response in women with locally advanced breast cancer using ultrasound elastography.

Authors:  Omar Falou; Ali Sadeghi-Naini; Sameera Prematilake; Ervis Sofroni; Naum Papanicolau; Sara Iradji; Zahra Jahedmotlagh; Sharon Lemon-Wong; Jean-Philippe Pignol; Eileen Rakovitch; Judit Zubovits; Jacqueline Spayne; Rebecca Dent; Maureen Trudeau; Jean Francois Boileau; Frances C Wright; Martin J Yaffe; Gregory J Czarnota
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

3.  Diffuse optical spectroscopy evaluation of treatment response in women with locally advanced breast cancer receiving neoadjuvant chemotherapy.

Authors:  Omar Falou; Hany Soliman; Ali Sadeghi-Naini; Sara Iradji; Sharon Lemon-Wong; Judit Zubovits; Jacqueline Spayne; Rebecca Dent; Maureen Trudeau; Jean Francois Boileau; Frances C Wright; Martin J Yaffe; Gregory J Czarnota
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

4.  Effect of HER2 status on distant recurrence in early stage breast cancer.

Authors:  Kenneth R Hess; Francisco J Esteva
Journal:  Breast Cancer Res Treat       Date:  2012-12-06       Impact factor: 4.872

5.  Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy.

Authors:  Albert Cerussi; David Hsiang; Natasha Shah; Rita Mehta; Amanda Durkin; John Butler; Bruce J Tromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

6.  Computer-aided evaluation of breast MRI for the residual tumor extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Chae Yeon Lyou; Nariya Cho; Sun Mi Kim; Mijung Jang; Jeong-Seon Park; Seung Yon Baek; Woo Kyung Moon
Journal:  Korean J Radiol       Date:  2011-01-03       Impact factor: 3.500

7.  Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.

Authors:  Bhumsuk Keam; Seock-Ah Im; Youngil Koh; Sae-Won Han; Do-Youn Oh; Nariya Cho; Jee Hyun Kim; Wonshik Han; Keon Wook Kang; Woo Kyung Moon; Tae-You Kim; In Ae Park; Dong-Young Noh; June-Key Chung; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2011-10-20       Impact factor: 4.430

8.  Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities.

Authors:  Ali Sadeghi-Naini; Lakshmanan Sannachi; Hadi Tadayyon; William T Tran; Elzbieta Slodkowska; Maureen Trudeau; Sonal Gandhi; Kathleen Pritchard; Michael C Kolios; Gregory J Czarnota
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

9.  Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.

Authors:  Bhumsuk Keam; Seock-Ah Im; Hee-Jun Kim; Do-Youn Oh; Jee Hyun Kim; Se-Hoon Lee; Eui Kyu Chie; Wonshik Han; Dong-Wan Kim; Woo Kyung Moon; Tae-You Kim; In Ae Park; Dong-Young Noh; Dae Seog Heo; Sung Whan Ha; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2007-11-01       Impact factor: 4.430

10.  Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture.

Authors:  Ali Sadeghi-Naini; Lakshmanan Sannachi; Kathleen Pritchard; Maureen Trudeau; Sonal Gandhi; Frances C Wright; Judit Zubovits; Martin J Yaffe; Michael C Kolios; Gregory J Czarnota
Journal:  Oncotarget       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.